TUSTIN, CA, Apr 13, 2010 (MARKETWIRE via COMTEX News Network) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical stage biopharmaceutical company developing novel monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from four clinical studies of bavituximab and Cotara(R) have been accepted for presentation at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 4-8, 2010 in Chicago, Illinois.

Abstracts Accepted at ASCO Phase II study of bavituximab plus docetaxel in locally advanced or metastatic breast cancer (Abstract #1042) Author: David Tabagari Saturday, June 5, 2:00-6:00 PM

Phase II study of bavituximab plus paclitaxel and carboplatin in locally advanced or metastatic breast cancer: Interim results (Abstract #1062) Author: Minish Jain Saturday, June 5, 2:00-6:00 PM

Phase II study of bavituximab plus paclitaxel and carboplatin in untreated locally advanced or metastatic non-small cell lung cancer: Interim results (Abstract #7589) Author: Raghunadharao Digumarti Sunday, June 6, 8:00 AM - 12:00 PM

Open-label, dose confirmation, and dosimetry study of interstitial 131I-chTNT-1/B MAb for the treatment of recurrent glioblastoma multiforme (GBM): Final results (Abstract #2039) Author: William R. Shapiro Sunday, June 6, 8:00 AM - 12:00 PM

For more information on the ASCO conference, visit http://chicago2010.asco.org/Home.aspx.

About Peregrine Pharmaceuticals Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara(R). Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Contacts:
GendeLLindheim BioCom Partners
Investors
Email Contact
(800) 987-8256

Media
Barbara Lindheim
(212) 918-4650

SOURCE: Peregrine Pharmaceuticals

http://www2.marketwire.com/mw/emailprcntct?id=3DCE247B7B82E9F5

Copyright 2010 Marketwire, Inc., All rights reserved.

News Provided by COMTEX